



(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/4985 (2006.01)
A61K 31/445 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/011578

(22) International Filing Date:

16 January 2024 (16.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/480,285 17 January 2023 (17.01.2023) US

(71) Applicant: **YARROW THERAPEUTICS, INC.**
[US/US]; 3031 Tisch Way, Suite 605, San Jose, California
95128 (US).

(72) Inventor: **GAVRILYUK, Julia**; 3031 Tisch Way, Suite
605, San Jose, California 95128 (US).

(74) Agent: **LOHREY, Trevor** et al.; Wilson Sonsini Goodrich
& Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: ECTEINASCIDIN DERIVATIVE ANTIBODY DRUG CONJUGATES




FIG. 1

(57) Abstract: Provided herein are compounds, methods, and pharmaceutical compositions for use in treatment of cancer. In certain embodiments, ecteinascidin derivative antibody drug conjugate compounds are provided which display remarkable efficacy and bioavailability for the treatment of, for example, cancer in a human.

[Continued on next page]

(88) Date of publication of the international search report:
22 August 2024 (22.08.2024)